Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 89.70
+3.35 (3.88%)
Jul 10, 2026, 4:08 PM HKT
Innovent Biologics Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Innovent Biologics stock has a consensus rating of "Strong Buy" and an average price target of $117.34. The average 1-year stock price forecast is 30.81% higher than the current stock price, while the lowest is $83.19 (-7.26%) and the highest is $158.18 (+76.34%).
Price Target: $117.34 (+30.81%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Innovent Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 21 | 21 | 22 | 22 | 22 | 22 |
| Buy | 4 | 5 | 5 | 6 | 6 | 6 |
| Hold | 3 | 3 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 29 | 29 | 30 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst UBS No rating | UBS | Buy Maintains $124.00 | Buy | Maintains | $124.00 | +38.24% | Jun 30, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $118.30 | Buy | Maintains | $118.30 | +31.88% | Jun 4, 2026 |
Unknown Analyst BOCOM International Holdings Company No rating | BOCOM International Holdings Company | Buy Maintains $105.00 | Buy | Maintains | $105.00 | +17.06% | Jun 4, 2026 |
Unknown Analyst CSC Financial No rating | CSC Financial | Buy Maintains $147.70 | Buy | Maintains | $147.70 | +64.66% | Jun 3, 2026 |
Unknown Analyst Morgan Stanley No rating | Morgan Stanley | Buy Maintains $135.00 | Buy | Maintains | $135.00 | +50.50% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
18.79B
from 13.04B
Increased by 44.08%
Revenue Next Year
22.18B
from 18.79B
Increased by 18.05%
EPS This Year
1.63
from 0.99
Increased by 64.92%
EPS Next Year
2.30
from 1.63
Increased by 40.75%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 30.4B | ||
| Avg | 18.8B | ||
| Low | 16.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 133.5% | ||
| Avg | 44.1% | ||
| Low | 25.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.70 | ||
| Avg | 1.63 | ||
| Low | 0.63 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 273.9% | ||
| Avg | 64.9% | ||
| Low | -36.3% |